Drugs / LMN-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04098263 | Nov 2019 → Apr 2020 | campylobacteriosis | Lumen Bioscience, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04182490 Comparator | Feb → Oct 2022 | campylobacteriosis | Lumen Bioscience, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMN-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04182490 ↗ |
| Action | Inhibit | “designed to bind and inhibit flagellin filament protein of Campylobacter jejuni” NCT04098263 ↗ |
| Modality | Protein / enzyme biologic | “variable heavy chain-derived binding protein” NCT04098263 ↗ |
| Route | Oral | “LMN-101 orally three times daily for 28 days” NCT04098263 ↗ |